Do you manage your residual risk?

Fig. (1). Relative risk reduction of the primary endpoint in different statin trials and remaining cardiovascular risk. Green: primary prevention trials, red: secondary  prevention trials, orange: comparison between aggressive and moderate lipid-lowering.

I think we should first manage lifestyle changes even in symptomatic patients...
http://www.ncbi.nlm.nih.gov/pubmed/15364185



Current Pharmaceutical Design, 2011, 17, 861-870